AstraZeneca - Articles and news items

severe asthma

New medicine shows potential to reduce oral steroid use in severe asthma patients

Industry news / 26 May 2017 / Niamh Marriott, Junior Editor

A trial led by a McMaster University respirology professor shows promising results for a new medicine for severe asthma patients.

Brilique (ticagrelor) new formulation gains European approval

Industry news / 25 May 2017 / Niamh Marriott, Junior Editor

The European Commission has granted marketing authorisation for AstraZeneca’s Brilique (ticagrelor) orodispersible tablets (ODT) as a new formulation…

Seloken

AstraZeneca enters agreement with Recordati for Seloken in Europe

Industry news / 24 May 2017 / Niamh Marriott, Junior Editor

AstraZeneca has entered into an agreement with Recordati for the commercial rights to Seloken/Seloken ZOK treatments in Europe…

Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research

Industry news / 16 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines

Inducing protein aggregation by extensional flow makes drugs less effective

Industry news / 9 May 2017 / University of Leeds

Data from a new device demonstrates maximal levels of extensional flow which manufacturers could use for different processes, without damaging proteins…

Roche receives FDA approval for bladder cancer biomarker assay

Industry news / 5 May 2017 / Niamh Marriott, Junior Editor

The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma…

formulation

AstraZeneca’s new formulation tablets receive positive CHMP opinion

Industry news / 5 May 2017 /

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the adoption of AstraZeneca’s Brilique (ticagrelor) 90mg orodispersible tablets (ODT) as a new method of treatment administration. This opinion is the first step towards the adoption of a new formulation of ticagrelor designed for […]

bladder

AstraZeneca’s bladder cancer treatment receives FDA approval

Industry news / 3 May 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) to treat metastatic urothelial carcinoma…

AstraZeneca’s lung cancer drug receives full approval in the EU

Industry news / 27 April 2017 / Niamh Marriott, Junior Editor

The EC has granted full marketing authorisation for AstraZeneca’s Tagrisso for the treatment of mutation-positive non-small cell lung cancer (NSCLC)…

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

New drug reduces daily menopausal hot flushes by 73%

Industry news / 6 April 2017 / Niamh Marriott, Junior Editor

In a trial carried out at Imperial College, researchers showed that women who suffered seven or more hot flushes a day could reduce the number by 73%…

AstraZeneca lung cancer drug receives FDA approval

Industry news / 4 April 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) to treat non-small cell lung cancer (NSCLC)…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+